Neurological
Refine Search
Pharmaceutical
Swiss pharma company Addex Therapeutics is to enter into a collaboration with the Dystonia Medical Research Foundation to explore the use of dipraglurant to treat dystonia. 19 January 2015
Generics
US drugmaker Supernus Pharmaceuticals says it has sued privately-held generics firm Par Pharmaceutical for infringement of four patents covering its antiepileptic drug Trokendi XR (topiramate). 19 January 2015
Biotechnology
UK-based C4X Discovery Holdings has entered into a research agreement with drug discovery alliance Evotec. 19 January 2015
Pharmaceutical
Neuropore Therapies, a wholly-owned US subsidiary of Austria’s Ever Neuro Pharma, has entered into a worldwide collaboration and agreement with Belgium’s largest drugmaker, UCB. 18 January 2015
Biotechnology
Australian biotech firm Novogen has announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells. 16 January 2015
Pharmaceutical
US specialty drugmaker Depomed has entered into a definitive agreement to acquire the US rights to the Nucynta (tapentadol) franchise from Johnson & Johnson subsidiary Janssen Pharmaceuticals, for $1.05 billion. 16 January 2015
Biotechnology
Netherlands-based biotech firm Treeway has entered into a collaboration with Dutch gene therapy company uniQure to develop a gene therapy treatment for ALS. 15 January 2015
Pharmaceutical
German family-owned drug major Boehringer Ingelheim is one of 35 partners from industry and academia who have come together to test innovative treatments for the prevention of Alzheimer’s dementia. 15 January 2015
Pharmaceutical
Japanese pharma company Sumitomo Dainippon and its US subsidiary Sunovion Pharmaceuticals have jointly filed patent infringement law suits against Emcure Pharmaceuticals and InvaGen Pharmaceuticals. 15 January 2015
Pharmaceutical
The US Food and Drug Administration has approved US drugmaker AbbVie’s Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson’s disease. 13 January 2015
Biotechnology
US biotech major Biogen Idec has agreed to acquire independent UK-based Convergence Pharmaceuticals, a clinical-stage biopharmaceutical company, in a deal that is expected to close during the first quarter of this year. 12 January 2015
Biotechnology
Switzerland’s biopharma company AC Immune has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals, a unit of US health care giant Johnson & Johnson to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer’s disease and potentially other tauopathies. 12 January 2015
Pharmaceutical
Swiss drugmaker Mundipharma Laboratories and its independent associated company, Purdue Pharmaceuticals, have entered into a global multi-program discovery and development collaboration with privately held Spanish firm Laboratorios Esteve. 12 January 2015
Biotechnology
US biotech firm Egalet Corp has in-licensing two innovative approved pain products transforming Egalet into a fully integrated specialty pharmaceutical company focused on developing and commercializing products indicated to treat patients living with moderate to severe pain. 9 January 2015
Pharmaceutical
Italy-based Newron Pharmaceuticals and its partner Zambon have received a recommendation from the Euroean Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) that the European Commission approve Xadago (safinamide). 7 January 2015
Biotechnology
Shares of Ireland-headquartered biotech firm Alkermes closed up 2.6% to $60.93, having risen as much as 5% yesterday, after the company has released positive top-line results from the FORWARD-1 study. 7 January 2015
Pharmaceutical
Ireland-headquartered generics major Actavis has had its motion to expedite its appeal of a lower court ruling requiring it to continue distribution of Namenda (memantine HCl) immediate-release tablets approved. 7 January 2015
Biotechnology
23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche, have joined forces to generate whole genome sequencing data for around 3,000 people in 23andMe's Parkinson's disease community. 6 January 2015
Pharmaceutical
The humble aspirin, originally used only as a pain killer but since has been identified as a factor in the fight against heart attacks and strokes, could also have an important role in the prevention of dementia. 5 January 2015
Pharmaceutical
Japanese drug major Eisai has announced a Phase III trial of antiepileptic drug Fycompa (perampanel) to treat patients with refractory partial-onset seizures met its primary endpoint. 5 January 2015
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze